Literature DB >> 18697942

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis.

Srinivasa P S Rao1, Sylvie Alonso, Lucinda Rand, Thomas Dick, Kevin Pethe.   

Abstract

The persistence of Mycobacterium tuberculosis despite prolonged chemotherapy represents a major obstacle for the control of tuberculosis. The mechanisms used by Mtb to persist in a quiescent state are largely unknown. Chemical genetic and genetic approaches were used here to study the physiology of hypoxic nonreplicating mycobacteria. We found that the intracellular concentration of ATP is five to six times lower in hypoxic nonreplicating Mtb cells compared with aerobic replicating bacteria, making them exquisitely sensitive to any further depletion. We show that de novo ATP synthesis is essential for the viability of hypoxic nonreplicating mycobacteria, requiring the cytoplasmic membrane to be fully energized. In addition, the anaerobic electron transport chain was demonstrated to be necessary for the generation of the protonmotive force. Surprisingly, the alternate ndh-2, but not -1, was shown to be the electron donor to the electron transport chain and to be essential to replenish the [NAD(+)] pool in hypoxic nonreplicating Mtb. Finally, we describe here the high bactericidal activity of the F(0)F(1) ATP synthase inhibitor R207910 on hypoxic nonreplicating bacteria, supporting the potential of this drug candidate for shortening the time of tuberculosis therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18697942      PMCID: PMC2575262          DOI: 10.1073/pnas.0711697105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Mycobacterium bovis BCG response regulator essential for hypoxic dormancy.

Authors:  Calvin Boon; Thomas Dick
Journal:  J Bacteriol       Date:  2002-12       Impact factor: 3.490

2.  Gene expression profile of Mycobacterium tuberculosis in a non-replicating state.

Authors:  D G Niranjala Muttucumaru; Gretta Roberts; Jason Hinds; Richard A Stabler; Tanya Parish
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

Review 3.  Nonreplicating persistence of mycobacterium tuberculosis.

Authors:  L G Wayne; C D Sohaskey
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

Review 4.  Tuberculosis. Scientific blueprint for tuberculosis drug development.

Authors: 
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

5.  Susceptibility of Mycobacterium tuberculosis to weak acids.

Authors:  Ying Zhang; Hao Zhang; Zhonghe Sun
Journal:  J Antimicrob Chemother       Date:  2003-05-29       Impact factor: 5.790

6.  Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy.

Authors:  M I Voskuil; K C Visconti; G K Schoolnik
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

7.  Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis.

Authors:  Heui-Dong Park; Kristi M Guinn; Maria I Harrell; Reiling Liao; Martin I Voskuil; Martin Tompa; Gary K Schoolnik; David R Sherman
Journal:  Mol Microbiol       Date:  2003-05       Impact factor: 3.501

8.  Reaction sites of rotenone, piericidin A, and amytal in relation to the nonheme iron components of NADH dehydrogenase.

Authors:  M Gutman; T P Singer; H Beinert; J E Casida
Journal:  Proc Natl Acad Sci U S A       Date:  1970-03       Impact factor: 11.205

9.  Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis.

Authors:  David M Roberts; Reiling P Liao; Goragot Wisedchaisri; Wim G J Hol; David R Sherman
Journal:  J Biol Chem       Date:  2004-03-19       Impact factor: 5.157

10.  Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment.

Authors:  Dirk Schnappinger; Sabine Ehrt; Martin I Voskuil; Yang Liu; Joseph A Mangan; Irene M Monahan; Gregory Dolganov; Brad Efron; Philip D Butcher; Carl Nathan; Gary K Schoolnik
Journal:  J Exp Med       Date:  2003-09-01       Impact factor: 14.307

View more
  219 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

Review 2.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

3.  Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Authors:  Rokeya Tasneen; Si-Yang Li; Charles A Peloquin; Dinesh Taylor; Kathy N Williams; Koen Andries; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 4.  TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Authors:  Alberto Matteelli; Anna Cc Carvalho; Kelly E Dooley; Afranio Kritski
Journal:  Future Microbiol       Date:  2010-06       Impact factor: 3.165

5.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

Review 6.  Adenylating enzymes in Mycobacterium tuberculosis as drug targets.

Authors:  Benjamin P Duckworth; Kathryn M Nelson; Courtney C Aldrich
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

7.  Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue.

Authors:  Anna C Haagsma; Rooda Abdillahi-Ibrahim; Marijke J Wagner; Klaas Krab; Karen Vergauwen; Jerome Guillemont; Koen Andries; Holger Lill; Anil Koul; Dirk Bald
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Polyphosphate deficiency in Mycobacterium tuberculosis is associated with enhanced drug susceptibility and impaired growth in guinea pigs.

Authors:  Ramandeep Singh; Mamta Singh; Garima Arora; Santosh Kumar; Prabhakar Tiwari; Saqib Kidwai
Journal:  J Bacteriol       Date:  2013-04-12       Impact factor: 3.490

Review 10.  Alanine dehydrogenases in mycobacteria.

Authors:  Ji-A Jeong; Jeong-Il Oh
Journal:  J Microbiol       Date:  2019-01-31       Impact factor: 3.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.